The SG-INSIGHT study in Singapore will sequence the whole genomes of about 450,000 residents, nearly 1 in 10 of the population, to advance precision medicine. Illumina has been selected to provide sequencing services, linking genomic data with health records to improve disease understanding and personalized healthcare. This Phase III study builds on earlier phases and aims to integrate genetic screening into Singapore's public healthcare system for better prevention and treatment. The project highlights Singapore's leadership in precision health and Illumina's commitment to local innovation and compliance with healthcare regulations.
Illumina, Inc. shares are trading at USD 227.00 on Pluang as of Nov 03, 2026 08:11 WIB. The stock has experienced a 3.81% decline in the past day. Its market capitalization stands at $35.63 billion, reflecting its significant presence in the health sector.
